BEST Initiative - New and Innovative Methods for Automated Reporting

The BEST Initiative Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract, awarded by the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), focuses on developing advanced automated reporting methodologies for biologics surveillance. The contract's primary objective is to create innovative data collection and analysis techniques using cutting-edge technologies such as natural language processing, artificial intelligence, and machine learning. These methods are specifically designed to enhance adverse event reporting and surveillance for CBER-regulated products, which include cell therapies, gene therapies, blood products, and vaccines.

International Business Machines Corporation (IBM) has been the primary contractor for this vehicle, consistently winning delivery orders ranging from approximately $7 million to $14.6 million. The task orders are time and materials contracts with durations typically spanning one to two years, with completion dates consistently falling around late September. All task orders to date have been awarded without specific set-aside designations, suggesting open competition. The contracts support the FDA's critical need to modernize and automate regulatory reporting processes for biologics, leveraging IBM's extensive experience in information technology and consulting for federal agencies. The work is predominantly performed in support of the Department of Health and Human Services, with a focus on enhancing the technological infrastructure for tracking and analyzing biologics safety and effectiveness.